18 results about "Obstructive lung disease" patented technology

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape as the devices are deployed into the tissue. This action causes the pulmonary treatment devices to corkscrew into damaged tissue, becoming sufficiently entwined to allow pulling of the tissue by retraction of the device. This in turn re-tensions the lung causing lung volume reduction.

This invention provides a traditional Chinese medicine composition for clearing the lungs and relieving asthma, its granules, and their applications, relating to the field of traditional Chinese medicine technology. The traditional Chinese medicine composition for clearing the lungs and relieving asthma of this invention is prepared from the following raw materials in the indicated weight proportions: Ephedra 8-12g, Earthworm 8-12g, Bitter Apricot Kernel 8-12g, Mulberry Bark 8-12g, Coltsfoot Flower 13-18g, Stemona 13-18g, Platycodon Root 8-12g, Prepared Pinellia Rhizome 8-12g, Tangerine Peel 8-12g, Ginkgo Root 8-12g, Scutellaria Root 13-18g, Perilla Seed 13-18g, Trichosanthes Peel 25-35g, Peucedanum Root 8-12g, and Belamcanda Rhizome 8-12g. The traditional Chinese medicine formula provided by this invention has good clinical efficacy in treating chronic obstructive pulmonary disease, with high clinical control and efficacy rates, and a high overall effective rate.

The application belongs to the technical field of medicine, and discloses application of a perilla leaf extract in preparation of a medicine for treating and / or preventing asthma-chronic obstructive pulmonary disease (ACO). The perilla leaf extract has a significant curative effect in treating and / or preventing ACO disease, can significantly improve aggregation of inflammatory cells in the lung of an ACO mouse and generation levels of inflammatory factors, and improve lung function and pathological changes of lung tissue inflammation; in addition, the perilla leaf extract can significantly inhibit generation of neutrophil inflammatory factors TNF-alpha, IL-6 and IL-1beta, and inhibit generation of an eosinophil inflammatory factor TNF-alpha.

The invention discloses an application of adenosine in preparing or preventing a chronic obstructive pulmonary disease, the chronic obstructive pulmonary disease refers to an acute exacerbation stage of the chronic obstructive pulmonary disease, and the acute exacerbation stage of the chronic obstructive pulmonary disease is caused by streptococcus pneumoniae; the medicine is used for inhibiting cell activation and proinflammatory factor release through an A2AR receptor. The invention provides a powerful scientific basis for application of adenosine in preparation of related drugs in treatment and prevention of lung diseases, especially chronic obstructive pulmonary diseases.

The invention discloses a heart and lung condition detection system for a patient with chronic obstructive pulmonary disease based on virtual reality, and belongs to the technical field of intelligent medical treatment. The problem that the cardiopulmonary state of a patient in daily activities is difficult to comprehensively reflect in the prior art is solved, data packet loss is found in time by detecting the time interval of the data stream, and data transmission errors are reduced in combination with monitoring of the data transmission rate; data are analyzed in combination with physiological rules, and untrusted data are removed; therefore, a reliable data basis is provided for cardiopulmonary function evaluation, and the rehabilitation effect can be improved. A multi-dimensional respiratory cycle portrait of a chronic obstructive pulmonary disease patient is analyzed in real time by constructing a cardiopulmonary function prediction model, and an abnormal mode deviating from a baseline is accurately recognized; a user behavior analysis mechanism is introduced to evaluate the psychological state and the rehabilitation effect, personalized early warning information and rehabilitation suggestions are generated, it is ensured that a patient can be intervened in time when abnormity occurs, and meanwhile the monitoring burden of medical staff is relieved.

The application discloses application of triacetylandrographolide and a composition thereof in preparation of a medicine for relaxing airway smooth muscle, and belongs to the technical field of medicines. In view of the problems of obvious side effects and narrow treatment window of existing medicines, the application finds that triacetylandrographolide (3, 14, 19-Triacetylandrographolide, TAA) and the composition thereof have tracheal relaxation activity, and the triacetylandrographolide and the composition thereof play a relaxation role through non-competitive antagonism of a downstream signal path of a cholinergic receptor. The new mechanism provides a new idea for developing a new bronchial dilator for overcoming drug resistance of existing medicines. The TAA after preparation optimization can be used for treating or preventing airway obstructive diseases such as asthma, chronic obstructive pulmonary disease, bronchitis and acute lung injury.

The invention provides an intelligent early warning intervention system for chronic obstructive pulmonary diseases, and relates to the technical field of medical instruments. Comprising a core host, the core host is integrated with an active multi-modal sensor arm and an integrated drug delivery arm, a patient can be actively guided to enter a standardized test posture, and high-quality multi-modal physiological data such as lung function, blood oxygen and breath sound are synchronously collected; an intelligent medicine bin and an automatic delivery mechanism are arranged in the intelligent medicine box, and accurate taking, delivery and auxiliary inhalation of medicine can be completed after early warning is triggered. The standardized seat assists in fixing the sitting posture of a patient through a physical guiding structure, and the wearable monitoring vest achieves respiratory rhythm monitoring and auxiliary sputum excretion. According to the system, all the modules are cooperated through the central controller, and a complete entity closed loop from standard monitoring to intelligent early warning to automatic intervention is constructed. The system effectively solves the problems that household lung function monitoring data is unreliable and intervention is difficult to execute after early warning, and the timeliness, safety and patient compliance of chronic disease management are remarkably improved.

The invention discloses application of a reagent for knocking down NOD1 in preparation of a medicine for treating chronic obstructive pulmonary disease, and relates to the technical field of biology. By knocking down NOD1, lung dysfunction caused by the chronic obstructive pulmonary disease can be improved, the lung function is improved, and an obvious prevention and treatment effect on the chronic obstructive pulmonary disease is achieved.

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

The application discloses a use of taibai araloside in treating hypoxic pulmonary arterial hypertension. In the use of hypoxia to induce pulmonary arterial hypertension, it is found that the taibai araloside can reduce right ventricular pressure and right heart hypertrophy index, and inhibit pulmonary arterial remodeling; the taibai araloside reduces the expression and activity of ACE in the lung in a concentration-dependent manner, and corrects the disorder of the RAS system in the lung caused by hypoxic pulmonary arterial hypertension. Moreover, a monomer component of the taibai araloside, anemarrhena asphodeloides glycoside and chizhenshan saponin IVa, has a stable combination with ACE. The results show that the taibai araloside has the potential to be developed into a drug for preventing and treating hypoxic pulmonary arterial hypertension in the clinic, and also provides a prevention and treatment strategy for interstitial lung disease, chronic obstructive pulmonary disease, sleep apnea syndrome, chronic high altitude disease and neonatal respiratory disease.

The present invention provides an obstructive lung disease biomarker and a method for using the same. This method for examining obstructive lung disease includes a step (1) of detecting at least one protein selected from the group consisting of a protein group (A), a protein group (B), a protein group (C), and a protein group (D) in a sample collected from a subject, wherein the sample is an extracellular vesicle from exhaled air and / or body fluid on the respiratory surface, or exhaled air and / or body fluid on the respiratory surface.

The invention discloses a viscera regulating and lung nourishing formula for chronic obstructive pulmonary disease complicated with osteopenia, and belongs to the technical field of traditional Chinese medicines. The invention discloses a formula for regulating viscera and nourishing lung. The formula is prepared from the following traditional Chinese medicines: 10-20 parts of codonopsis pilosula, 6-15 parts of rhizoma atractylodis macrocephalae fried with bran, 6-15 parts of white mulberry root-bark, 1.5-6 parts of bulbus fritillariae cirrhosae, 10-20 parts of fructus lycii, 10-20 parts of semen cuscutae, 12-20 parts of adenophora tetraphylla, 12-20 parts of radix glehniae, 6-15 parts of radix paeoniae alba, 9-18 parts of raw astragalus membranaceus, 9-12 parts of officinal magnolia bark, 9-18 parts of roasted aster, 9-18 parts of roasted tussilago farfara and 6-15 parts of ligusticum wallichii. An oral preparation can be prepared by taking the formula as a raw material and adding pharmaceutically acceptable auxiliary materials, and the oral preparation can be divided into three types, namely a solid, a liquid and a paste, and can be specifically selected from a plurality of dosage forms, such as decoction, granules and the like. The viscera regulating and lung nourishing prescription can be used for preparing a medicine for treating chronic obstructive pulmonary disease stable phase combined bone mass reduction, plays a role by regulating bone metabolism balance, is reasonable in compatibility and diverse in dosage form, and provides a new choice for clinical treatment.

The invention belongs to the field of biological medicine, and particularly relates to a scutellarin and luteolin compatible composition and application thereof. In particular discloses a scutellarin and luteolin compatible composition as shown in formulas (I) and (II), and the scutellarin and luteolin compatible composition is applied to treatment and / or prevention of chronic obstructive pulmonary diseases. The screened scutellarin and luteolin compatible composition is simple in preparation method, has a remarkable synergistic treatment effect on the chronic obstructive pulmonary disease, and has a remarkable treatment effect on airway inflammation and lung function impairment of a mouse with the chronic obstructive pulmonary disease induced by a cigarette smoke extract; meanwhile, the composition shows a remarkable inhibiting effect on a neutrophile granulocyte extracellular trap net released by LPS-induced primary mouse bone marrow neutrophile granulocyte, TNF-alpha and IL-6 in vitro, the two medicines have a synergistic effect, the improvement effect is obviously superior to that of a single medicine, and the compatible composition has a relatively high development and application value in treatment of the chronic obstructive pulmonary disease.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape as the devices are deployed into the tissue. This action causes the pulmonary treatment devices to corkscrew into damaged tissue, becoming sufficiently entwined to allow pulling of the tissue by retraction of the device. This in turn re-tensions the lung causing lung volume reduction.

The invention discloses an alpha, beta unsaturated ketone substituted chromone derivative of which the structure is shown as a formula I or pharmaceutically acceptable salt and isomer I thereof. The compound can realize efficient selective inhibition on a BLT1 receptor through a specific molecular action mechanism, shows nanomole-level BLT1 inhibition activity and excellent selectivity, and meanwhile, shows a remarkable treatment effect in acute lung injury, chronic obstructive pulmonary disease and sepsis models. The invention discloses an application of the alpha, beta unsaturated ketone substituted chromone derivative or the pharmaceutically acceptable salt and isomer thereof in preparation of a BLT1 inhibitor, and also discloses an application of the alpha, beta unsaturated ketone substituted chromone derivative or the pharmaceutically acceptable salt and isomer thereof in preparation of the BLT1 inhibitor. The invention discloses an application of the alpha, beta unsaturated ketone substituted chromone derivative or the pharmaceutically acceptable salt and isomer thereof in preparation of medicines for treating acute lung injury, chronic obstructive pulmonary disease and sepsis, and also discloses an application of the alpha, beta unsaturated ketone substituted chromone derivative or the pharmaceutically acceptable salt and isomer thereof in preparation of medicines for treating acute lung injury, chronic obstructive pulmonary disease and sepsis.

The invention therefore provides methods of treating a respiratory disease characterized by mucus hyper-secretion comprising administering to a human patient in need of such treatment a gamma secretase inhibitor (GSI), wherein the administration of a GSI is effective in reducing mucus in such patient's lungs or inhibiting mucus accumulation in said patient's lungs. In some embodiments, the methods of the invention are effective in treating a respiratory disease selected from the group consisting of cystic fibrosis, chronic obstructive pulmonary disease, primary ciliary dyskinesis, chronic bronchitis, asthma, idiopathic and secondary bronchiectasis, bronchiolitis obliterans, idiopathic pulmonary fibrosis, respiratory infection and mucus accumulation in response to infection. Methods of the invention further include methods of treating cystic fibrosis wherein a GSI is administered to a patient being administered or in need of a CFTR modulator, wherein the mucus in such patient's lungs is reduced or mucus accumulation in such patient's lungs is inhibited.

The application relates to the technical field of combined medicines, and discloses application of a Dachaihu decoction combined with crocin in preparation of AECOPD medicines, which comprises the Dachaihu decoction and crocin, and the mass ratio of the Dachaihu decoction to the crocin is 284:5; wherein the mass of the Dachaihu decoction is recorded according to the mass of medicinal materials. The Dachaihu decoction has the advantages of small side effect and high safety in treatment of AECOPD, and the crocin can improve the lung function of patients in the acute exacerbation period of chronic obstructive pulmonary disease by down-regulating the expression of NLRP3, inhibit oxidation stress and inflammatory reaction, and inhibit alveolar epithelial cell apoptosis. The Dachaihu decoction is creatively combined with the crocin, and the combination can play a synergistic role in treatment of the acute exacerbation period of chronic obstructive pulmonary disease, so that the Dachaihu decoction combined with the crocin has an application prospect of development into a medicine for treatment of the acute exacerbation period of chronic obstructive pulmonary disease.

The invention discloses application of an NOP2 expression inhibitor in preparation of a medicine for preventing and treating chronic obstructive pulmonary disease. It is found that by inhibiting expression of targeted NOP2, lung tissue damage of chronic obstructive pulmonary disease model mice can be effectively improved, lung tissue inflammatory response is inhibited, and lung functions are improved. Therefore, the NOP2 expression inhibitor has the prospect of being developed into the medicine for preventing or treating the chronic obstructive pulmonary disease, and the NOP2 expression inhibitor is nucleic acid (such as RNA interference fragment shRNA, siRNA, miRNA, dsRNA and the like of targeted NOP2) for inhibiting NOP2 expression or a carrier (such as a plasmid carrier and a virus carrier) capable of releasing or expressing the nucleic acid.